Cargando…
Metformin therapy as a strategy to compensate anti-VEGF resistance in patients with diabetic macular edema
Diabetic macular edema (DME) is the complication of diabetic retinopathy, the leading cause of vision loss among diabetic patients. Metformin is the main antidiabetic treatment. It is preferable for its great anti-angiogenic and anti-inflammatory effects. Anti-vascular endothelial growth factor (VEG...
Autores principales: | Uwimana, Alexandre, Ma, Cong, Chen, Shengyao, Ma, Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592524/ https://www.ncbi.nlm.nih.gov/pubmed/36281139 http://dx.doi.org/10.1097/MD.0000000000031266 |
Ejemplares similares
-
Effect of microaneurysms on the anti-VEGF treatment for diabetic macular edema: A retrospective cross-sectional study
por: Watanabe, Akira, et al.
Publicado: (2023) -
Characteristics of diabetic macular edema patients with serous retinal detachment
por: Hwang, Hyung Bin, et al.
Publicado: (2019) -
Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol
por: Sugimoto, Masahiko, et al.
Publicado: (2017) -
Association Between Diabetic Macular Edema and Cardiovascular Events in Type 2 Diabetes Patients: A Multicenter Observational Study
por: Leveziel, Nicolas, et al.
Publicado: (2015) -
Concurrent injection of dexamethasone intravitreal implant and anti-angiogenic agent in patients with macular edema: A retrospective cohort study
por: Lin, Hung-Yu, et al.
Publicado: (2017)